Molecular Formula | C22H21N3O3S |
Molar Mass | 407.49 |
Solubility | 10 mM in DMSO |
Appearance | powder |
Color | white to beige |
Storage Condition | 2-8°C |
Stability | Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 2 months. |
In vitro study | ANA-12 can selectively bind directly to the TrkB receptor and inhibit the TrkB downstream pathway without changing the function of TrkA and TrkC. In nnr5 PC12-TrkB cells, 10 nM of ANA-12 prevented brain-derived neurotrophic factor (BDNF)-mediated neurite outgrowth. In DRG neurons, ANA-12 abolished the effect of BDNF to increase inward currents. |
In vivo study | In adult C57BL6/129svev F1s mice, ANA-12 (0.5 mg/kg, I. P.) reduced brain TrkB activity and ameliorated anxiety-and depression-related behaviors without affecting neuronal survival. ANA-12 (0.5 mg/kg, I. P.) showed an antidepressant effect on lipopolysaccharide-induced depressive behavior in male C57BL/6 mice. In male Sprague-Dawley rats, ANA-12 (3 μg/Dose) blocked the feeding-reducing effect of the medial subnucleus of the solitary tract (mNTS) BDNF. ANA-12 reversed alcohol intake and down-regulated D3 receptor expression in male wild-type mice, but was ineffective in D3R-/-type mice. In male CocSired rats, intraperitoneal injection of ANA-12(0.5 mg/kg) reversed the attenuation of cocaine self-administration. |
Hazard Symbols | Xn - Harmful |
Risk Codes | 22 - Harmful if swallowed |
WGK Germany | 3 |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.454 ml | 12.27 ml | 24.541 ml |
5 mM | 0.491 ml | 2.454 ml | 4.908 ml |
10 mM | 0.245 ml | 1.227 ml | 2.454 ml |
5 mM | 0.049 ml | 0.245 ml | 0.491 ml |
biological activity | ANA-12 is a selective TrkB antagonist, the Kd for the high and low affinity sites were 10 nM and 12 μm, respectively. |